Total Payments
$982,914
2024 Payments
$78,208
Companies
28
Transactions
474
Medicare Patients
11
Medicare Billing
$1,759
Payment Breakdown by Category
Consulting$691,847 (70.4%)
Other$176,206 (17.9%)
Research$73,887 (7.5%)
Travel$28,990 (2.9%)
Food & Beverage$8,727 (0.9%)
Education$3,257 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $691,847 | 193 | 70.4% |
| Honoraria | $101,381 | 26 | 10.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $74,825 | 21 | 7.6% |
| Unspecified | $73,887 | 40 | 7.5% |
| Travel and Lodging | $28,990 | 59 | 2.9% |
| Food and Beverage | $8,727 | 130 | 0.9% |
| Education | $3,257 | 5 | 0.3% |
Payments by Type
General
$909,027
434 transactions
Research
$73,887
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $209,499 | 72 | $0 (2021) |
| Lilly USA, LLC | $179,593 | 88 | $0 (2024) |
| PFIZER INC. | $91,662 | 52 | $0 (2024) |
| Grifols Shared Services North America, Inc. | $70,256 | 9 | $0 (2024) |
| Eli Lilly and Company | $68,856 | 44 | $0 (2024) |
| ABBVIE INC. | $68,400 | 36 | $0 (2024) |
| Amgen Inc. | $60,286 | 41 | $0 (2022) |
| H. Lundbeck A S | $50,557 | 26 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $36,566 | 7 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $33,161 | 22 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $78,208 | 34 | PFIZER INC. ($32,096) |
| 2023 | $108,500 | 77 | PFIZER INC. ($54,066) |
| 2022 | $133,268 | 38 | Grifols Shared Services North America, Inc. ($47,363) |
| 2021 | $157,374 | 42 | Lilly USA, LLC ($36,450) |
| 2020 | $173,400 | 52 | Allergan, Inc. ($64,500) |
| 2019 | $116,899 | 85 | Eli Lilly and Company ($38,850) |
| 2018 | $116,168 | 75 | Allergan Inc. ($36,504) |
| 2017 | $99,097 | 71 | Allergan Inc. ($46,658) |
All Payment Transactions
474 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $3,200.00 | Research |
| Study: NURTEC CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 12/17/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $3,200.00 | Research |
| Study: NURTEC CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 12/10/2024 | PFIZER INC. | ZAVZPRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,150.00 | General |
| Category: PAIN | ||||||
| 12/05/2024 | H. Lundbeck A S | VYEPTI (Biological) | Food and Beverage | In-kind items and services | $71.00 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $1,145.50 | General |
| 12/04/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $714.30 | General |
| 11/20/2024 | Axsome Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,875.00 | General |
| 11/20/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $130.86 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/14/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.09 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | PFIZER INC. | ZAVZPRET (Drug) | Travel and Lodging | In-kind items and services | $1,107.97 | General |
| Category: PAIN | ||||||
| 10/15/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: PAIN | ||||||
| 10/15/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $330.00 | Research |
| Study: NURTEC CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 08/01/2024 | PFIZER INC. | NURTEC ODT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: PAIN | ||||||
| 06/18/2024 | Eli Lilly and Company | EMGALITY (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Neuroscience | ||||||
| 06/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $47.12 | General |
| Category: NEUROLOGY | ||||||
| 06/05/2024 | PFIZER S.A. | NURTEC ODT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: PAIN | ||||||
| 05/15/2024 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 05/13/2024 | PFIZER INC. | ZAVZPRET (Drug), NURTEC ODT | — | In-kind items and services | $940.00 | Research |
| Study: ZAVZPRET CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 05/13/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $330.00 | Research |
| Study: RIMEGEPANT SULFATE CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 04/30/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $6,100.00 | General |
| Category: PAIN | ||||||
| 04/23/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PAIN | ||||||
| 03/27/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $544.75 | General |
| Category: PAIN | ||||||
| 03/18/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $133.87 | General |
| Category: PAIN | ||||||
| 03/07/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $3,200.00 | Research |
| Study: RIMEGEPANT SULFATE ZAVEGEPANT MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RANDOMIZED CONTROLLED TRIAL OF LASMIDITAN OVER FOUR MIGRAINE ATTACKS | Eli Lilly and Company | $19,286 | 1 |
| RIMEGEPANT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $16,640 | 19 |
| Phase 2 Chronic Migraine Prophylaxis | Amgen Inc. | $7,712 | 3 |
| NURTEC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,730 | 3 |
| RIMEGEPANT SULFATE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,730 | 3 |
| Reversion From Chronic Migraine to Episodic Migraine Following Treatment With Erenumab: Results of | Amgen Inc. | $6,625 | 1 |
| RIMEGEPANT SULFATE ZAVEGEPANT MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Migraine-related disability, impact, and quality of life among patients with episodic migraine receiving preventive treatment with erenumab | Amgen Inc. | $2,602 | 1 |
| Phase 3 Pivotal EMP (STRIVE) | Amgen Inc. | $1,382 | 1 |
| Long-term efficacy of erenumab in chronic migraine patients with acute medication overuse | Amgen Inc. | $1,103 | 2 |
| ZAVZPRET CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $750.00 | 1 |
| Conversion from Chronic to Episodic Migraine with Erenumab, a Specific Inhibitor of the Calcitonin Gene-related Peptide Receptor | Amgen Inc. | $90.85 | 1 |
| Living with Migraine and Economic Burden from Patients Perspective in United States: Results from My Migraine Voice Survey | Amgen Inc. | $66.79 | 1 |
| Conversion from Chronic to Episodic Migraine with Erenumab | Amgen Inc. | $29.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 11 | 21 | $9,870 | $1,759 |
Total Patients
11
Total Services
21
Medicare Billing
$1,759
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 11 | 21 | $9,870 | $1,759 | 17.8% |
About Dr. Richard Lipton, MD
Dr. Richard Lipton, MD is a Neurology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407931728.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Lipton, MD has received a total of $982,914 in payments from pharmaceutical and medical device companies, with $78,208 received in 2024. These payments were reported across 474 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($691,847).
As a Medicare-enrolled provider, Lipton has provided services to 11 Medicare beneficiaries, totaling 21 services with total Medicare billing of $1,759. Data is available for 1 year (2021–2021), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Bronx, NY
- Active Since 10/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407931728
Products in Payments
- NURTEC ODT (Drug) $96,175
- BOTOX (Biological) $86,083
- UBRELVY (Drug) $69,379
- VYEPTI (Biological) $62,456
- Aimovig (Biological) $50,721
- Gamunex-C (Biological) $40,993
- Albutein (Biological) $27,763
- EMGALITY (Drug) $19,744
- AJOVY (Drug) $15,240
- ZAVZPRET (Drug) $15,198
- BOTOX - MIGRAINE (Drug) $12,116
- ONZETRA Xsail (Drug) $11,000
- AMG334A_AIMOVIG_NEUROSCIENCE (Biological) $7,802
- QULIPTA (Drug) $6,687
- MAYZENT (Drug) $6,599
- TEV-48125 (Biological) $5,880
- AJOVY (Biological) $4,153
- ELYXYB - CELECOXIB (Drug) $3,300
- GILENYA (Drug) $3,071
- REYVOW (Drug) $3,000
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Bronx
Michael Thorpy, Md, MD
Neurology — Payments: $451,587
Neurology $451,587
Rene Elkin, Md, MD
Neurology — Payments: $343,327
Neurology $343,327
Jelena Pavlovic, M.d, M.D
Neurology — Payments: $130,235
Neurology $130,235
Dr. Sandeep Gulati, D.o, D.O
Neurology — Payments: $124,853
Neurology $124,853
Dr. Lauren Gluck, Md, MD
Neurology — Payments: $53,848
Neurology $53,848
Christopher Langston
Neurology — Payments: $46,700
Neurology $46,700